Impulse Control Disorder, Parkinson Disease
Conditions
Keywords
Deep brain stimulation
Brief summary
The goal of this experimental study with is to understand the underlying mechanisms behind the increase in impulsivity seen in some patients that undergo deep brain stimulation of the subthalamic nucleus for Parkinson's Disease. The main questions it aims to answer are: What are the distributed network effects of deep brain stimulation to the subthalamic nucleus? How does this correlate with increased impulsivity? Can alternative stimulation settings be used to minimize these? Participants will complete decision-making tasks whilst their deep brain stimulation devices are turned on and off with simultaneous magnetoencephalography recordings (a type of non-invasive brain scan that measures brain activity in real-time)
Interventions
OTHERDBS on/off
DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
Sponsors
University of Oxford
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Two groups of patients will be recruited: * Parkinson's disease patients treated with deep brain stimulation and no impulse control disorder * Parkinson's disease patients treated with deep brain stimulation and impulse control disorder (an increase in QUIP-RS after surgery)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy. * Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease. * Participant willing and able to sit in the MEG scanner and follow instructions. * Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time).
Exclusion criteria
* Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter. * Other implanted medical devices that may cause artefacts during MEG recordings. * Participants with a history of co-morbid neurological disorders. * Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study. * Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify effect of therapeutic STN-DBS on frontosubthalamic networks in PD related ICDs during decision making and impulse control | 12 months | Correlation between response time and accuracy with electrophysiological signatures of neural activity. |
Countries
United Kingdom
Contacts
Primary ContactJohn Eraifej, BSc MBChB MRCS
Outcome results
None listed